The currently available data suggests that patients with inflammatory rheumatic conditions do not exhibit an increased frequency of COVID-19 infection or a more severe course of the disease in general. General risk factors –such as older age, obesity, cardiovascular conditions, chronic lung conditions, hypertension, and diabetes– seem to be much more important in this respect.
During a unique virtual press conference, Prof. Gerd Burmester (EULAR Public Affairs Officer; Charité University Hospital, Germany) addressed some issues regarding medication, inflammatory rheumatic disease, and COVID-19 infection . He emphasised that discontinuing immunomodulatory medication is not a good idea, as patients with inflammatory rheumatic diseases do not have an increased frequency of infection with COVID-19, nor do they experience a more severe course of the infection. Moreover, stopping therapy may trigger a relapse of the disease, which may lead to an unfavourable ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Anifrolumab achieves rapid and durable BICLA-response Next Article
Letter from the Editor »
Table of Contents: EULAR 2020
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.